What do you view as the optimal use and timing of cemiplimab in high risk CSCC?  

Increasingly, neoadjuvant cemiplimab has become our preferred approach for many patients with resectable high-risk CSCC, and this is consistent with what several high-volume centers are now doing. The high pathologic response rates, durable recurrence-free survival in responders, and meaningful surg...

The landscape of immunotherapy in CSCC is quickly evolving, with multiple studies underway to help delineate the best clinical applications of this class of medications. Adjuvant therapy with cemiplimab is preferred in patients who have extremely high-risk factors and have undergone surgery and adju...

Until we have a study directly comparing neoadjuvant vs adjuvant cemiplimab, we won't have a clear answer as to which approach is superior. All we can do at the present time is to look at the neoadjuvant vs adjuvant melanoma trials (i.e., SWOG 1801, NADINA), which have shown superior outcomes with n...